Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Focus Diagnostics Receives FDA Clearance for Moderate Complexity Simplexa® HSV MDx

Published: Monday, March 24, 2014
Last Updated: Thursday, March 27, 2014
Bookmark and Share
The test uses a proprietary process that eliminates nucleic acid extraction, so clinicians can expect results within about an hour after providing a specimen for testing.

Quest Diagnostics announced that its Focus Diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler. The test, which is now available for purchase in the United States, is the first molecular test to be cleared by the FDA for the qualitative detection and differentiation of herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) in cerebrospinal fluid (CSF) from patients suspected of HSV central nervous system (CNS) infection, including encephalitis. 

Encephalitis is an inflammation of the brain often caused by the herpes simplex or other viruses. The Infectious Diseases Society of America (IDSA) recommends herpes simplex PCR testing on all CSF specimens in patients with encephalitis.  HSV encephalitis occurs in all ages and during all seasons, with HSV-1 encephalitis more common in adults and HSV-2 encephalitis more common in newborn infants. Accurate determination of the virus causing encephalitis can influence treatment decisions and outcomes.

The moderate complexity categorization of the Simplexa HSV 1 & 2 Direct molecular test significantly broadens the potential clinical access to the technology. Moderate complexity laboratories, defined by the Clinical Laboratory Improvement Amendments (CLIA), include certain types of physician’s offices, community hospitals, health clinics and integrated delivery networks. These facilities typically lack the personnel and technology to perform high complexity molecular diagnostic tests. Since the test can be performed in these moderate complexity labs, patient results may be obtained readily to help speed therapeutic decisions.

"Diagnosing encephalitis is a major health challenge because determining the virus causing the condition shapes clinical decision making, yet most diagnostic tools, are slow to perform and may delay therapy,” said Kay Myrdal, Vice President and General Manager of Focus Diagnostics. “Our Simplexa HSV 1 & 2 Direct test’s ability to rapidly detect and distinguish HSV 1 & 2 in the spinal fluid of a patient suspected of suffering from encephalitis is critically important to clinical treatment decisions. This new assay is an important step in innovations that bring diagnostic insights closer to the patient, to help promote better care and outcomes.”

Simplexa tests, designed for use on the 3M™ Integrated Cycler, employ real-time polymerase chain reaction (PCR) technology to detect DNA or RNA in viruses, bacteria, and other analytes. Simplexa HSV 1 & 2 Direct is intended to aid in the diagnosis of HSV central nervous system (CNS) infection using CSF from patients suspected of HSV infections of the CNS. Simplexa tests use a proprietary chemistry that eliminates the need for nucleic acid extraction, which involves purifying nucleic acids from a specimen.  Nucleic acid extraction is an expensive and time-consuming process requiring specialized equipment and trained personnel.

“The nucleic acid extraction process, used in most commercial molecular test kits, can add approximately 60 to 90 minutes to the total time to result. Focus Diagnostics replaced the extraction process in our Simplexa products with a proprietary chemistry and technology,” said Michelle Tabb, Ph.D, Vice President, Research and Development for Focus Diagnostics. “Simplexa HSV 1 & 2 Direct results, like those of other Simplexa Direct test products, are available in about an hour from receiving a specimen for testing. This is a major advantage when dealing with an acute neurological condition like encephalitis.”

Simplexa HSV 1 & 2 Direct showed strong performance in clinical studies, with 100% and 98% sensitivity for detection of HSV-1 and HSV-2 respectively. The test was CE marked for distribution to more than 30 countries in Europe in November 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Clears Focus Diagnostics and 3M Test for Molecular Influenza and Respiritory Virus
First moderate-complexity Simplexa™ assay developed through funding by U.S. Department of Health and Human Services' BARDA BAA program for public health preparedness.
Wednesday, October 10, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Measuring the Abundance of Extremely Rare Mutations
Researchers from Rutgers University demonstrate the use of multiplex real-time PCR assays to measure the abundance of extremely rare mutations associated with cancer.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Finding Zika One Paper Disc At A Time
A novel, inexpensive method for detecting the Zika virus could help slow spread of outbreak, and potentially other future pandemic diseases.
Rapid Diagnosis of Bacterial Infections
Mass. General-developed compact system could shorten diagnostic time from days to hours, bring testing to point of care.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Gene Analysis System Could Accelerate Pace of Research on the Space Station
The WetLab-2 system will enable spaceflight genomic studies involving a wide variety of biospecimen types in the unique microgravity environment of space.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!